Navigation Links
Keryx Biopharmaceuticals Announces Upcoming Corporate Presentations
Date:2/5/2008

NEW YORK, Feb. 5 /PRNewswire-FirstCall/ -- Keryx Biopharmaceuticals, Inc. (Nasdaq: KERX) today announced that Michael S. Weiss, the Company's Chairman and Chief Executive Officer, will be presenting at the following upcoming Investor Conferences:

Thursday, February 7th, 2008 - 10:20 AM ET:

Merrill Lynch 19th Global Pharmaceutical, Biotechnology & Medical Device Conference
Grand Hyatt Hotel

New York City

Monday, February 11, 2008 - 12:30 PM ET:

BIO CEO & Investor Conference

Waldorf=Astoria Hotel

New York City

Each of Mr. Weiss' presentations will be webcast live and may be accessed from the Investor Information page of the Company's Website at http://investors.keryx.com. An archived version of each presentation webcast will be available following the conclusion of the live presentation.

About Keryx Biopharmaceuticals, Inc.

Keryx Biopharmaceuticals, Inc. is focused on the acquisition, development and commercialization of medically important, novel pharmaceutical products for the treatment of life-threatening diseases, including diabetes and cancer. Keryx's lead compound under development is Sulonex(TM) (sulodexide oral gelcap), previously referred to as KRX-101, a first-in-class, oral heparinoid compound for the treatment of diabetic nephropathy, a life-threatening kidney disease caused by diabetes. Sulonex is in a pivotal Phase 3 and Phase 4 clinical program under a Special Protocol Assessment with the Food & Drug Administration. Additionally, Keryx is developing Zerenex(TM), an oral, iron- based compound that has the capacity to bind phosphate and form non-absorbable complexes. Zerenex is currently in Phase 2
'/>"/>

SOURCE Keryx Biopharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Keryx Biopharmaceuticals, Inc. Announces Third Quarter 2007 Financial Results
2. Keryx Biopharmaceuticals, Inc. to Hold Conference Call on Third Quarter 2007 Financial Results on Thursday, October 25, at 8:30 A.M. EDT
3. Keryx Biopharmaceuticals, Inc. Enters into Licensing Agreement with Japan Tobacco and Torii Pharmaceutical for Development and Commercialization of Hyperphosphatemia Drug in Japan
4. Keryx Biopharmaceuticals, Inc. Announces Conference Call to Discuss Strategic Alliance
5. Keryx Biopharmaceuticals, Inc. Announces Appointment of Michael P. Tarnok to Board of Directors
6. Keryx Biopharmaceuticals to Present at Bank of America Investment Conference
7. Nabi Biopharmaceuticals to Present at the BMO Capital Markets Focus on Healthcare Conference
8. China Biopharmaceuticals Holdings Announces Third Quarter 2007 Financial Results
9. Nabi Biopharmaceuticals Stockholders Approve Asset Sale
10. Nventa Biopharmaceuticals Corporation announces third-quarter 2007 financial results
11. RiskMetrics Group (ISS) and Glass Lewis & Co. Support Nabi Biopharmaceuticals Proposed Asset Sale
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/17/2014)...   Synageva BioPharma Corp. (NASDAQ: ... rare disorders, announced today its presentation at the upcoming ... San Francisco, CA. Sanj ... present on Monday, January 12, 2015, at 9:00 a.m. ... live and may be accessed from the "Webcasts & ...
(Date:12/15/2014)... DIEGO , Dec. 15, 2014 ... three-dimensional biology company focused on delivering breakthrough 3D ... the industry and collaborators of its exVive3D TM ... made widely available in full commercial release on ... the field, resulting in several awards for innovation. ...
(Date:12/15/2014)... Denmark , Dec. 15, 2014  Ascendis ... innovative TransCon technology to address significant unmet medical ... its ongoing Phase 2 pediatric study to evaluate ... hormone deficiency, or GHD.  This interim analysis consists ... anticipated total enrollment in the study, completing all ...
(Date:12/13/2014)... Rockville, Maryland (PRWEB) December 12, 2014 ... Maryland, today announced its new name: Therabron Therapeutics ... words therapy and bronchioles (a type of structure in ... incorporating the company’s mission to develop novel protein therapeutics ... board of directors decided to change the name to ...
Breaking Biology Technology:Organovo Celebrates a Positive 2014 Reception of its exVive3DTM Human Liver Tissue Product 2Organovo Celebrates a Positive 2014 Reception of its exVive3DTM Human Liver Tissue Product 3Ascendis Pharma A/S Announces Positive Six-Month Interim Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 2Ascendis Pharma A/S Announces Positive Six-Month Interim Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 3Ascendis Pharma A/S Announces Positive Six-Month Interim Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 4Maryland-based Biotech Company's Path Forward in Treating Respiratory Diseases Sparks Name Change 2
... Fintan Walton talks exclusively to Johnson & Johnson ... Ventures, latest fund announced today at BIO-Europe Spring in ... Index,s largest existing limited partners and two companies, GSK ... companies of J&J (Janssen). Francesco De Rubertis ...
... which not only exhibits characteristics ideal to use in underwater ... run out of energy thanks to it being fuelled by ... which have the ability to change shape or size as ... able to mimic the natural movements of a jellyfish when ...
... prospects for superior new organic electronic devices are brighter ... the U.S. Department of Energy (DOE),s Lawrence Berkeley National ... a DOE nanoscience center, the team has provided the ... charge is transported from molecule-to-molecule in an organic thin ...
Cached Biology Technology:PTV Interview Exclusive: Revolutionary GSK and J&J Participation in New Index Ventures Fund 2Jellyfish inspires latest ocean-powered robot 2Better organic electronics 2Better organic electronics 3
(Date:12/3/2014)... , Dec. 2, 2014   Marvin Test ... innovative test solutions for military, aerospace, and manufacturing ... of its successful TS-900 PXI semiconductor test ... features of high-end systems to customers at a ... compared to traditional ATE. "Our ...
(Date:11/21/2014)... According to a new market research report ... Control, Intrusion Detection, Parking Management, Under Vehicle Inspection), End ... - Global Forecasts to 2020", published by MarketsandMarkets, The ... $25 Billion in 2014 and is expected to reach ... 8.69%. Browse 116 market data Tables and ...
(Date:11/21/2014)... VIEW, Calif. , Nov. 20, 2014 ... higher driver efficiency are piloting the North American and ... number of accidents growing, gesture recognition systems that are ... make a mark in the industry. ... the Automotive Gesture Recognition Market in Europe ...
Breaking Biology News(10 mins):Marvin Test Solutions Brings New Capabilities to PXI-Based Semiconductor Test with TS-960 2Marvin Test Solutions Brings New Capabilities to PXI-Based Semiconductor Test with TS-960 3Industrial Security Systems Market Worth $38 Billion by 2020 2Industrial Security Systems Market Worth $38 Billion by 2020 3Gesture Recognition Intensifies with the Rise of In-car Smartphone Integration, Says Frost & Sullivan 2Gesture Recognition Intensifies with the Rise of In-car Smartphone Integration, Says Frost & Sullivan 3Gesture Recognition Intensifies with the Rise of In-car Smartphone Integration, Says Frost & Sullivan 4
... ,Global chemical companies could release at least one billion ... performance. The claim has been made following ... nine global chemical companies in monetary terms. Entitled Sustainable ... by a leading European research team including academics from ...
... population carry Helicobacter pylori ( H. pylori ) ... population are infected. Besides cancer, these bacteria are linked to ... the H. pylori genome in 1997 revealed this ... a number of crucial questions: Where do the genes of ...
... 3025 MONALISA has developed a new, completely natural alternative to ... and to prevent the damaging effects of the fungal toxins ... for use in animal feed in the EU since 2006 ... The already-known capacity of clay minerals to adsorb these mycotoxins ...
Cached Biology News:Study highlights sustainable footprint of chemical companies 2Study highlights sustainable footprint of chemical companies 3Gene regulation: Can we stomach it? 2French and Spanish researchers develop a natural alternative to antibiotics in animal feed 2French and Spanish researchers develop a natural alternative to antibiotics in animal feed 3
Tube-O-DIALYZER Floats, small....
Nestin, Human...
Rabbit polyclonal to Survivin DEx3 ( Abpromise for all tested applications). entrezGeneID: 332 SwissProtID: O15392...
Smac/DIABLO (mouse) (CT) rabbit polyclonal antibody...
Biology Products: